相关实验视频
Updated: May 9, 2025

06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
9.7K
来自Gynostemma pentaphyllum的一种多糖:通过调节加勒-3的结构特征和抗胰岛素耐药性潜力
Mingwang Ren1, Guoqing Sun2, Xiaoyu Ding3
1School of Pharmacy, Zunyi Medical University, Zunyi 563006, China; Department of Laboratory Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi 563003, China.
International journal of biological macromolecules
|April 30, 2025
概括
来自Gynostemma pentaphyllum的一种新型多糖,GPPA1-1,通过抑制Galactin-3有效地对抗胰岛素抵抗. 这一发现为代谢障碍提供了潜在的新疗法策略.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 代谢研究研究 代谢研究
背景情况:
- 多糖是Gynostemma pentaphyllum中重要的生物活性化合物.
- 胰岛素耐药性是一个日益严重的代谢健康问题.
- 加勒-3在胰岛素抵抗的发展中起作用.
研究的目的:
- 从Gynostemma pentaphyllum中分离和表征一种新型的多糖分 (GPPA1-1) .
- 研究GPPA1-1在缓解胰岛素抵抗方面的潜力.
- 阐明其作用机制,特别是抑制加勒-3.
主要方法:
- 使用柱状染色学将GPPA1-1分离和净化.
- 通过FT-IR,甲基化和NMR分析进行结构阐明.
- 生物评估包括加列克-3抑制试验,西式涂抹,CETSA和葡萄糖吸收试验.
主要成果:
- 隔离GPPA1-1的分子量为3.7 × 10^4 Da,由特定的单糖组成.
- 结构分析揭示了复杂的多糖骨干和分支模式.
- 通过抑制加勒-3蛋白,GPPA1-1在缓解胰岛素抵抗方面表现出显著的有效性.
结论:
- GPPA1-1是一种来自Gynostemma pentaphyllum的新型生物活性多糖体.
- 通过抑制加列克-3 (Galectin-3) 来控制胰岛素抵抗,GPPA1-1具有治疗潜力.
- 对GPPA1-1的进一步研究可能会导致对代谢疾病的新疗法.
更多相关视频
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
117
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
117
Glucagon-like Receptor Agonists
250
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
250
Oligosaccharide Assembly
2.7K
Protein glycosylation starts in the ER lumen and continues in the Golgi apparatus. Glycosyltransferases catalyze the addition of sugar molecules or glycosylation of proteins. Usually, these enzymes add sugars to the hydroxyl groups of selected serine or threonine residues to form O-linked glycans or the amino groups of asparagine residues to form N-linked glycans. Different positions on the same polypeptide chain can contain differently linked glycans.
Multiple sugar molecules that may or may...
Multiple sugar molecules that may or may...
2.7K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
106
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
106
Protein Glycosylation
6.4K
Glycosylation, the most common post-translational modification for proteins, serves diverse functions. Adding sugars to proteins makes the proteins more resistant to proteolytic digestion. Glycosylated proteins can act as markers and receptors to promote cell-cell adhesion. Additionally, they have many essential quality control functions in the cell, such as correct protein folding and facilitating transport of misfolded proteins to the cytosol, which can be degraded.
Glycosylation occurs in...
Glycosylation occurs in...
6.4K
Proteoglycans
3.8K
Glycans, a class of complex heterogeneous molecules, can be covalently attached to proteins to form glycosylated proteins that regulate various physiological and pathological processes. Glycosylated proteins or glycoproteins comprise N-linked and O-linked oligosaccharides. O-glycosylation is the most common type of protein glycosylation. Here, glycans attach to the oxygen atom of the hydroxyl groups of Serine or Threonine residues. O-linked glycosylation occurs later in protein processing,...
3.8K

